MassBio’s President & CEO, Bob Coughlin, will host a weekly virtual Town Hall for members, taking place every Tuesday at 11am. This will be an opportunity for our members to ask questions, hear what MassBio is up to, and learn more about the state of the industry amidst the COVID-19 pandemic.
For this Town Hall, Bob will be joined by Chuck Wilson, CEO of Unum Therapeutics and Chair of the MassBio Board of Directors, to talk about how he will lead MassBio and the industry through the next two years in terms of capitalizing on opportunities for growth, addressing systemic challenges, and creating a more sustainable future.
Webinar link will be emailed to participants the day before - you can also access it from the "Live Stream" tab below. This event is for members-only.
NOTE: MassBio makes every effort to accommodate our entire community at each of our events. Please let us know at least 3 days in advance of the event if you require special accommodations, such as captioning.
As President and CEO of the Massachusetts Biotechnology Council, Bob’s mission is to advance Massachusetts' leadership in the life sciences to grow the industry, add value to the healthcare system and improve patient lives. Over the last decade, Bob has truly become a champion for patients by ensuring innovative companies have the best environment possible to research, develop, and commercialize breakthrough therapies and cures for people around the world who need and deserve them.
Bob has spent his career in both the public and private sectors. Before joining MassBio, he served as the Undersecretary of Economic Development within Governor Deval Patrick's administration, where he prioritized both healthcare and economic development issues and was a strong advocate for the life sciences industry in Massachusetts. Prior to that, he was elected as State Representative to the 11th Norfolk district for three terms. Bob has also held senior executive positions in the environmental services, capital management and venture capital industries. He brings passion and energy to all of his endeavors.
President and CEO of Unum Therapeutics, and Chair, MassBio Board of Directors
Charles (‘Chuck’) Wilson is President and Chief Executive Officer of Unum Therapeutics, a company developing a novel cellular immunotherapy platform for the treatment of cancer. Prior to joining Novartis, Chuck co-founded Archemix, a Cambridge, MA biotech company focused on the development of aptamers as therapeutics. At Archemix, Chuck served as Chief Technology Officer, responsible for both developing the company’s technology platform and managing its drug discovery efforts. As part of the senior management team, Chuck helped the company raise over $100 million in equity financing and grow to approximately 100 employees, advancing multiple programs into clinical development. Before moving into industry, Chuck was a professor in the Markey Center for the Molecular Biology of RNA at the University of California, Santa Cruz. There he determined the first x-ray crystal structures of RNA aptamers bound to their targets and developed such molecules as tools for regulating gene expression. Trained in structural biology and molecular biology, Chuck received his PhD with David Agard (UCSF, HHMI) and did his postdoctoral training with Nobelist Jack Szostak (Havard University / Massachusetts General Hospital).
Immediately prior to starting Unum, Chuck served as Vice President, Global Head of Strategic Alliances for the Novartis Institutes for BioMedical Research (NIBR), the research and early development division of Novartis. In this role he was responsible for leading partnering efforts across all disease areas up through clinical proof-of-concept. His efforts included academic and biotech collaborations, equity investing in early stage companies, in- licensing of compounds, and spin-out of assets/technologies to start ups.